Lumipulse® G PIVKA-II
Getting a better view on liver cancer
Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of protein induced vitamin K absence or antagonist-II (PIVKA-II) in serum.
The assay utilises proven CLEIA (ChemiLuminescent Enzyme Immunoassay) technology with results that are available in up to 35 minutes.
Product number 233184
Product number 233191
Click here to navigate
- Related products
- Product inquiry
- Allows stratification of patients on transplant waiting list.
- Predicts recurrence of HCC.
Complementary to AFP for improved detection of (early) HCC.
Only assay available on an automated platform (LUMIPULSE G1200)
Oncology menu available for routine, specialized and unique markers
Calibrators and controls available
Different clinical applications:
Monitoring: Correlation with microvascular invasion, recurrence and tumor size
Diagnosis: Complementary to AFP for the improved detection of HCC
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide with a high rate of mortality and an increasing incidence.
The most common causes of HCC are either a viral hepatitis infection (hepatitis B or C) or cirrhosis (alcoholism being the most common cause of hepatic cirrhosis).
The starting point in the diagnostic surveillance of at risk patients is ultrasound.
In a second stage this can be completed with the measurement of a tumor marker called α-fetoprotein (AFP).
Since ultrasound has a poor performance in cirrhotic patients and is also operator dependent, further characterization by CT or MRI is often required.
As it is important to detect HCC at an early stage when the disease is still curable, biomarkers can complete the diagnosis obtained with ultrasound before moving on to the more expensive MRI.
Biomarkers can also be used to better stratify patients on the liver transplant waiting list.
Additionally, the risk of recurrence of HCC after transplantation can be assessed by monitoring patients with biomarkers.
CLEIA - ChemiLuminescent Enzyme Immunoassay
See the LUMIPULSE G1200 working in this video:
PIKVA-II (Protein Induced Vitamin K Absence or Antagonist-II) is an immature form of prothrombin also known as DCP (Des-gamma-Carboxy Prothrombin)...
Sep 25, 2015
Lumipulse® PIVKA-II and KL-6 Control
Product number 233801 -
Assayed control serum to monitor the precision of laboratory testing procedures for the analysis of PIVKA-II and KL-6 using LUMIPULSE Systems.CE marked
Lumipulse® G HBcIgM
Product number 231494 -
Immunoreaction cartridges set for in vitro diagnostics (IVD) use with the LUMIPULSE G System for the qualitative detection of IgM antibody to hepatitis B core antigen (anti-HBc IgM) in human serum or plasma.CE marked
Lumipulse® G HBcrAg
Product number 294109 -
Immunoreaction cartridges set for Research Use Only (not for use in diagnostic precedures) with the LUMIPULSE G System for the quantitative detection of hepatitis B virus core-related antigen in serum or plasma.For research use only
Lumipulse® G HBeAb-N
Product number 233108 -
Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the qualitative detection of antibody to hepatitis B e antigen (anti-HBe) in human serum or plasma. This product is indicated as an aid in the diagnosis and monitoring of hepatitis B viral infection and for professional use only.CE marked
Lumipulse® G HBeAg
Product number 231517 -
Immunoreaction cartridges set for in vitro diagnostics (IVD) use with the LUMIPULSE G System for the qualitative detection of hepatitis B e antigen (HBeAg) in human serum or plasma. This product is indicated as an aid in the diagnosis and monitoring of hepatitis B viral infection and for professional use only.CE marked
Lumipulse® G HBsAg-Quant
Product number 296851 -
Immunoreaction cartridges for in vitro diagnostics (IVD) use with the LUMIPULSE G System for the qualitative and quantitative detection of hepatitis B surface antigen (HBsAg) in human serum or plasma.CE marked
Product number 703380 -
The LUMIPULSE G600II is the latest member of the Lumipulse G series of chemiluminescent enzyme immunoassay analyzers (CLEIA) from Fujirebio.CE marked